(STMN) Straumann Holding - SW
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: SW (Switzerland) | Market Cap: 14.928m CHF | Total Return: 0.1% in 12m
Avg Turnover: 31.9M
Qual. Beats: 0
Rev. Trend: 100.0%
Qual. Beats: 0
Warnings
Overextended 3d
Tailwinds
Squeeze
Straumann Holding AG is a global leader in tooth replacement and orthodontic solutions, headquartered in Basel, Switzerland. The company develops and manufactures dental implants, biomaterials, CADCAM prosthetics, and clear aligners. Its business model integrates hardware, such as 3D printers and intra-oral scanners, with digital software and artificial intelligence to support the entire clinical workflow from diagnosis to restoration.
The dental implant industry is characterized by high barriers to entry due to stringent regulatory requirements and the need for extensive clinical validation. Straumann maintains a multi-brand strategy, utilizing subsidiaries like Neodent and Anthogyr to address different price points and geographic markets, ranging from premium to value segments.
The company’s revenue is diversified across major regions, including EMEA, North America, and Asia Pacific, supported by a direct sales force and an extensive e-commerce platform. Investors may find it useful to examine ValueRay for deeper insights into the companys valuation and long-term growth trends. Founded in 1954, Straumann has evolved from a family-owned research institute into a comprehensive provider of regenerative, restorative, and orthodontic dentistry.
- Premium implant segment volume growth drives group revenue and margins
- Market share expansion in China via value-brand portfolio and volume-based procurement
- ClearCorrect aligner penetration scales orthodontic segment revenue and profitability
- Emerging market demand and digital workflow adoption accelerate global sales growth
| Net Income: 356.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -1.30 > 1.0 |
| NWC/Revenue: 34.65% < 20% (prev 23.14%; Δ 11.51% < -1%) |
| CFO/TA 0.13 > 3% & CFO 504.4m > Net Income 356.3m |
| Net Debt (344.5m) to EBITDA (1.31b): 0.26 < 3 |
| Current Ratio: 2.21 > 1.5 & < 3 |
| Outstanding Shares: last quarter (158.4m) vs 12m ago -0.70% < -2% |
| Gross Margin: 68.72% > 18% (prev 70.95%; Δ -2.23% > 0.5%) |
| Asset Turnover: 70.06% > 50% (prev 69.19%; Δ 0.87% > 0%) |
| Interest Coverage Ratio: 75.22 > 6 (EBIT TTM 1.15b / Interest Expense TTM 15.3m) |
| A: 0.24 (Total Current Assets 1.65b - Total Current Liabilities 743.6m) / Total Assets 3.82b |
| B: 0.75 (Retained Earnings 2.88b / Total Assets 3.82b) |
| C: 0.31 (EBIT TTM 1.15b / Avg Total Assets 3.72b) |
| D: 1.31 (Book Value of Equity 2.16b / Total Liabilities 1.65b) |
| Altman-Z'' = 7.46 = AAA |
| DSRI: 1.03 (Receivables 604.5m/561.8m, Revenue 2.60b/2.50b) |
| GMI: 1.03 (GM 70.95% / 68.72%) |
| AQI: 1.00 (AQ_t 0.38 / AQ_t-1 0.38) |
| SGI: 1.04 (Revenue 2.60b / 2.50b) |
| TATA: -0.04 (NI 356.3m - CFO 504.4m) / TA 3.82b) |
| Beneish M = -2.94 (Cap -4..+1) = A |
As of June 19, 2026, the stock is trading at CHF 105.15 with a total of 685,511 shares traded.
Over the past week, the price has changed by +9.64%,
over one month by +21.99%,
over three months by +27.50% and
over the past year by +0.14%.
Straumann Holding has no consensus analysts rating.
P/E Trailing = 41.9821
P/E Forward = 29.8507
P/S = 5.7296
P/B = 6.9094
P/EG = 1.4357
Revenue TTM = 2.60b CHF
EBIT TTM = 1.15b CHF
EBITDA TTM = 1.31b CHF
Long Term Debt = 473.7m CHF (from longTermDebt, last quarter)
Short Term Debt = 35.3m CHF (from shortTermDebt, last quarter)
Debt = 819.9m CHF (from shortLongTermDebtTotal, last quarter) + Leases 169.2m
Net Debt = 344.5m CHF (calculated: Debt 819.9m - CCE 475.4m)
Enterprise Value = 15.3b CHF (14.9b + Debt 819.9m - CCE 475.4m)
Interest Coverage Ratio = 75.22 (Ebit TTM 1.15b / Interest Expense TTM 15.3m)
EV/FCF = 46.46x (Enterprise Value 15.3b / FCF TTM 328.7m)
FCF Yield = 2.15% (FCF TTM 328.7m / Enterprise Value 15.3b)
FCF Margin = 12.62% (FCF TTM 328.7m / Revenue TTM 2.60b)
Net Margin = 13.68% (Net Income TTM 356.3m / Revenue TTM 2.60b)
Gross Margin = 68.72% ((Revenue TTM 2.60b - Cost of Revenue TTM 814.9m) / Revenue TTM)
Gross Margin QoQ = 65.10% (prev 72.09%)
Tobins Q-Ratio = 4.00 (Enterprise Value 15.3b / Total Assets 3.82b)
Interest Expense / Debt = 1.86% (Interest Expense 15.3m / Debt 819.9m)
Taxrate = 21.33% (97.1m / 455.1m)
NOPAT = 903.0m (EBIT 1.15b * (1 - 21.33%))
Current Ratio = 2.21 (Total Current Assets 1.65b / Total Current Liabilities 743.6m)
Debt / Equity = 0.38 (Debt 819.9m / totalStockholderEquity, last quarter 2.16b)
Debt / EBITDA = 0.26 (Net Debt 344.5m / EBITDA 1.31b)
Debt / FCF = 1.05 (Net Debt 344.5m / FCF TTM 328.7m)
Total Stockholder Equity = 2.06b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.58% (Net Income 356.3m / Total Assets 3.82b)
RoE = 17.32% (Net Income TTM 356.3m / Total Stockholder Equity 2.06b)
RoCE = 45.36% (EBIT 1.15b / Capital Employed (Equity 2.06b + L.T.Debt 473.7m))
RoIC = 30.31% (NOPAT 903.0m / Invested Capital 2.98b)
WACC = 9.05% (E(14.9b)/V(15.7b) * Re(9.47%) + D(819.9m)/V(15.7b) * Rd(1.86%) * (1-Tc(0.21)))
Discount Rate = 9.47% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -17.98 | Cagr: -0.42%
[DCF] Terminal Value 71.70% ; FCFF base≈340.7m ; Y1≈318.1m ; Y5≈291.3m
[DCF] Fair Price = 23.68 (EV 4.12b - Net Debt 344.5m = Equity 3.78b / Shares 159.5m; r=9.05% [WACC]; 5y FCF grow -8.37% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.03 | # QB: 0
Revenue Correlation: 99.99 | Revenue CAGR: 3.93% | SUE: -0.02 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=3.11 | Chg30d=+0.59% | Revisions=+0% | GrowthEPS=+4.5% | GrowthRev=+5.4%
EPS next Year (2027-12-31): EPS=3.66 | Chg30d=+0.41% | Revisions=-38% | GrowthEPS=+17.4% | GrowthRev=+9.8%
[Analyst] Revisions Ratio: -38%